CLINICAL TRIALS PROFILE FOR INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
✉ Email this page to a colleague
All Clinical Trials for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00487240 ↗ | Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes | Completed | Eli Lilly and Company | Phase 3 | 2007-06-01 | The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives. |
NCT00494013 ↗ | Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) | Completed | Eli Lilly and Company | Phase 3 | 2007-08-01 | The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin therapy in adults with type 2 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives. |
NCT00510952 ↗ | Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) | Completed | Eli Lilly and Company | Phase 3 | 2007-08-01 | The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes. |
NCT00560417 ↗ | Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide | Completed | Eli Lilly and Company | Phase 3 | 2007-11-01 | This study will compare insulin lispro protamine suspension (ILPS) and insulin glargine in combination with the patient's oral diabetes medications and exenatide, for their ability to control blood sugar in patients with type 2 diabetes. |
NCT00641407 ↗ | Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes | Completed | Second University of Naples | Phase 4 | 2007-01-01 | The maintenance of nearly normal glycemic levels reduces the risk of diabetic complications, but is difficult to achieve, despite the administration of escalating doses of oral antidiabetic drugs, such as metformin, sulfonylureas, and thiazolidinediones. Most patients eventually require insulin which usually is added when glycemic control with a regimen of oral antidiabetic agents becomes suboptimal. The aims of the present study were: 1) To compare the clinical efficacy of insulin glargine and neutral protamine lispro (NPL) insulin when added to ongoing oral therapy in poorly controlled type 2 diabetic patients; 2) to find out the possibility to phenotype the patient who may benefit more by the single treatment. This an open-label, randomized, parallel, 36-week comparative study was performed between January 2007 and March 2008 at a single centre. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Condition Name
Condition MeSH
Clinical Trial Locations for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Trials by Country
Clinical Trial Progress for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Clinical Trial Phase
Clinical Trial Sponsors for Insulin Lispro Protamine Recombinant; Insulin Lispro Recombinant
Sponsor Name